Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting results this Monday after market hours. Here’s what to ...

在最新的市场动态中，Hims & Hers Health (HIMS.US) ...

Hims & Hers Health, Inc.（纳斯达克股票代码：HIMS）首席法务官Soleil Boughton于2025年7月28日以每股58.70美元的价格出售了2,572股A类普通股，总价值为150,976美元。

Investing.com - Hims Hers Health Inc ...

2025年7月21日，保健护理服务公司Hims & Hers Health（HIMS）成交额为12.73亿美元，在当日美股中排第60名，成交额较昨日增加15.76%，当日成交量为2612.34万。

周三，Hims & Hers Health (HIMS.US)涨超7%，月内累涨30%，报64.51美元。消息面上，该公司将于美东时间08月04日盘后发布财报，机构预期2025Q2实现营收5.52亿美元，同比增加74.89%;预期每股收益0.165美元，同比增加174.5%。

Hims & Hers Health ($HIMS) is scheduled to announce its results for the second quarter of 2025 after the market closes on Monday, August 4. HIMS ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

Hims & Hers Health 与诺和诺德的Wegovy合作仅持续两个月便因复配药合法性和营销争议破裂，引发前者股价单日暴跌和多起投资者诉讼。对于Hims & Hers Health 业绩基本面的冲击主要体现在法律/品牌成本及未来诺和诺德GLP-1正品供应的不确定性;若诉讼定责、复配受限，同时毛利持续下滑，则对中期盈利构成实质压力。

Hims & Hers Health ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the ...

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the Stocks With Huge Catalysts on the Horizon. On July 9, Hims & Hers Health, ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to controversial practices around the sale of compounded drugs. These drugs are ...